JPS6452722A - Ophthalmic composition - Google Patents
Ophthalmic compositionInfo
- Publication number
- JPS6452722A JPS6452722A JP10738588A JP10738588A JPS6452722A JP S6452722 A JPS6452722 A JP S6452722A JP 10738588 A JP10738588 A JP 10738588A JP 10738588 A JP10738588 A JP 10738588A JP S6452722 A JPS6452722 A JP S6452722A
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmological
- polysiloxane
- agent
- formula
- silicone polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PURPOSE: To obtain a composition for ophthalmological treatment, containing an ophthalmological agent and a nonirritating and nontoxic polysiloxane not clouding a field of view. CONSTITUTION: This new composition for ophthalmological treatment containing a silicone polymer liquid is obtained by blending a polysiloxane of the formula (R and R<1> to R<7> are each an alkyl, an aralkyl or its mixture; (n) is a number selected so as to regulate the viscosity of the polysiloxane to 3-70 centistoke) with any of various ophthalmological agents. An excipient comprising a well- known ophthalmological oil as a base is unsuitable because it clouds a field of view. The silicone polymer of the formula can be made into an ophthalmological therapeutic agent by combining it with an oxazolidine known as phenylephrine or dapiprazole of mydriatic agent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/045,913 US4879304A (en) | 1987-05-01 | 1987-05-01 | Ophthalmic compositions and process for preparing |
| EP88101032A EP0288659A1 (en) | 1987-05-01 | 1988-01-25 | Therapeutic opthalmic compositions containing silicone polymer fluids and a process for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6452722A true JPS6452722A (en) | 1989-02-28 |
Family
ID=26113600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10738588A Pending JPS6452722A (en) | 1987-05-01 | 1988-04-28 | Ophthalmic composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS6452722A (en) |
| AU (1) | AU609803B2 (en) |
| CA (1) | CA1309348C (en) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501806A (en) * | 2004-06-08 | 2008-01-24 | オキュラリス ファーマ， インコーポレイテッド | Hydrophobic ophthalmic composition and method of use |
| JP2013542239A (en) * | 2010-11-11 | 2013-11-21 | ノバリック ゲーエムベーハー | Liquid pharmaceutical composition for the treatment of posterior ocular diseases |
| JP2014531401A (en) * | 2011-07-26 | 2014-11-27 | アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Two-part formulation for ocular delivery |
| US9757459B2 (en) | 2010-10-20 | 2017-09-12 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US9757460B2 (en) | 2012-01-23 | 2017-09-12 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| US9770508B2 (en) | 2012-09-12 | 2017-09-26 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US10369117B2 (en) | 2012-09-12 | 2019-08-06 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11413323B2 (en) | 2018-10-12 | 2022-08-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US12226422B2 (en) | 2018-04-27 | 2025-02-18 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| US12496326B2 (en) | 2016-12-23 | 2025-12-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
-
1988
- 1988-04-28 JP JP10738588A patent/JPS6452722A/en active Pending
- 1988-04-29 CA CA000565504A patent/CA1309348C/en not_active Expired - Fee Related
- 1988-04-29 AU AU15315/88A patent/AU609803B2/en not_active Ceased
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501806A (en) * | 2004-06-08 | 2008-01-24 | オキュラリス ファーマ， インコーポレイテッド | Hydrophobic ophthalmic composition and method of use |
| US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10525062B2 (en) | 2010-03-17 | 2020-01-07 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US11324757B2 (en) | 2010-03-17 | 2022-05-10 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US9757459B2 (en) | 2010-10-20 | 2017-09-12 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US9968678B2 (en) | 2010-10-20 | 2018-05-15 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US11160865B2 (en) | 2010-10-20 | 2021-11-02 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| JP2013542239A (en) * | 2010-11-11 | 2013-11-21 | ノバリック ゲーエムベーハー | Liquid pharmaceutical composition for the treatment of posterior ocular diseases |
| US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
| US10813999B2 (en) | 2011-05-25 | 2020-10-27 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
| US11844836B2 (en) | 2011-05-25 | 2023-12-19 | Dermaliq Therapeutics, Inc. | Topical pharmaceutical composition based on semifluorinated alkanes |
| JP2014531401A (en) * | 2011-07-26 | 2014-11-27 | アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Two-part formulation for ocular delivery |
| JP2018062521A (en) * | 2011-07-26 | 2018-04-19 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Two part formulation for ophthalmic delivery |
| USRE49758E1 (en) | 2012-01-23 | 2023-12-19 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| US9757460B2 (en) | 2012-01-23 | 2017-09-12 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| US10576154B2 (en) | 2012-09-12 | 2020-03-03 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US12005033B2 (en) | 2012-09-12 | 2024-06-11 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US10449164B2 (en) | 2012-09-12 | 2019-10-22 | Novaliq Gmbh | Methods of treating ocular disorders using semifluorinated alkanes |
| US10369117B2 (en) | 2012-09-12 | 2019-08-06 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US10058615B2 (en) | 2012-09-12 | 2018-08-28 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US9770508B2 (en) | 2012-09-12 | 2017-09-26 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US11583513B2 (en) | 2012-09-12 | 2023-02-21 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US11987623B2 (en) | 2013-07-23 | 2024-05-21 | Novaliq Gmbh | Stabilized antibody compositions |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| US11357738B2 (en) | 2015-09-30 | 2022-06-14 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US12128010B2 (en) | 2015-09-30 | 2024-10-29 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US11400132B2 (en) | 2016-09-23 | 2022-08-02 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US12496326B2 (en) | 2016-12-23 | 2025-12-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US11273174B2 (en) | 2017-04-21 | 2022-03-15 | Novaliq Gmbh | Iodine compositions |
| US12150955B2 (en) | 2017-04-21 | 2024-11-26 | Dermaliq Therapeutics, Inc. | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| US12226422B2 (en) | 2018-04-27 | 2025-02-18 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| US11413323B2 (en) | 2018-10-12 | 2022-08-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12059449B2 (en) | 2018-10-12 | 2024-08-13 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1531588A (en) | 1988-11-03 |
| CA1309348C (en) | 1992-10-27 |
| AU609803B2 (en) | 1991-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6452722A (en) | Ophthalmic composition | |
| BR9714270A (en) | Liquid skin cleansing composition | |
| DE3787188D1 (en) | Viscous preparation for use on wounds in the cornea. | |
| EP0524968A4 (en) | Heterovesicular liposomes | |
| GR1001503B (en) | Method for the preparation of pharmaceutical compounds containing carbonic acids containing sulphur and the use thereof in fighting retroviruses. | |
| MY101791A (en) | New benzimidazole derivatives | |
| AR008387A1 (en) | NEW 5-PHENOXIALKYL-THIAZOLIDIN-2,4-DIONES, PROCEDURES FOR OBTAINING THEM, NEW INTERMEDIATE COMPOUNDS OF THESE PROCEDURES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE NEW 5-PHENOXIALKYL-TIAZOLIDIN- 2,4-DIAZES | |
| MX24839A (en) | 3-ARYCARBONYL-1-AMINOALKYL-1H-INDOLES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION WHICH IT CONTAINS. | |
| ATE38991T1 (en) | 2-POSITION-SUBSTITUTED 1,3PROPYLEDENDEPHOSPHONATE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| FR2391215A1 (en) | NEW IMIDAZOAZINES AND IMIDAZODIAZINES, THEIR PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS | |
| WO1999030722A8 (en) | Pharmaceutical compositions for mucolysis and treatment of inflammation | |
| FR2456104A1 (en) | NOVEL PYRAZINOBENZODIAZEPINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | |
| IT1196423B (en) | BENZOTIAZOLIN-COMPOUNDS | |
| ATE21905T1 (en) | NITROSUREA DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| ES2053055T3 (en) | PROCESS FOR THE PREPARATION OF A ENDERMIC MEDICINE WITH A GEL BASE. | |
| US3467756A (en) | Composition and method for treating glaucoma | |
| SU1517173A1 (en) | Antiseptic agent | |
| EP0204172A3 (en) | Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use | |
| ES2053590T3 (en) | 3-PHENYL-7H-TIAZOLO (3,2-B) (1,2,4) TRIAZIN-7-ONAS SUBSTITUTED, PROCEDURE FOR THEIR PREPARATION, MEDICINES CONTAINING THEM AND THEIR USE, AS WELL AS SOME INTERMEDIATE PRODUCTS FORMED DURING THE PREPARATION OF THE MENTIONED COMPOUNDS. | |
| KR910011258A (en) | How to Treat Glaucoma | |
| ATE37359T1 (en) | (2-((NITROPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND SALTS, THEIR USE IN MEDICINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE PREPARATION OF (2((AMINOPYRIDINYL)AMINO)PHENYL)ARYLMETHANONES AND PYRIDO(1,4) BENZODIAZEPINS. | |
| FR2258376A1 (en) | 10-Aza prostaglandins - for treatment of blood pressure and gastro-intestinal disorders and in prepn for confinement | |
| KR870002050A (en) | Ocular Selective β-Blockers | |
| FR2655989B1 (en) | NOVEL SUBSTITUTED AMINO ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| KR880000094A (en) | Gastritis Treatment |